QIAGEN Partners to Develop Novel Companion Diagnostic in Lung Cancer

Collaboration with Mirati Therapeutics targets MET gene mutations to personalize treatment

13 Apr, 2016, 16:05 ET from QIAGEN N.V.

HILDEN, Germany and GERMANTOWN, Maryland, April 13, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with Mirati Therapeutics, Inc. (NASDAQ: MRTX) to co-develop and commercialize a companion diagnostic test to guide the use of Mirati's glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer (NSCLC). The companies aim to create a regulator-approved test to personalize treatment decisions in NSCLC by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene.

"We are pleased to partner with Mirati to commercialize a standardized companion diagnostic paired with glesatinib, a compound now in Phase II trials for NSCLC patients with cancer-driving MET alterations. Delivering insights on these clinically actionable variants holds potential to significantly improve clinical outcomes," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "This companion diagnostic for glesatinib is the initial effort under a master collaboration agreement and we continue to discuss potential future projects across various sample types and platforms, such as PCR and NGS, to further expand targeted diagnostic capabilities in this arena."

Click here for full press release

Public Relations:

Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 Email: pr@qiagen.com http://www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com

Investor Relations:

John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: ir@qiagen.com ir.qiagen.com

SOURCE QIAGEN N.V.